Phase 3 clinical trials provided evidence that afatinib produces significantly longer progression-free survival (PFS) than gefitinib as a first-line EGFR-TKI treatment for EGFR common mutations (exon19 deletion and L858R) in patients with positive non-small cell lung cancer (NSCLC), and higher efficacy in patients with EGFR minor mutations such as G719X and L861Q [3,4]. Here, EGFR is linked to non-small cell lung carcinoma.